Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
In development
Reference number: GID-TA11221
Expected publication date: TBC
NICE has received 1 appeal that falls within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisation:
Eli Lilly and Company Limited
The appeal panel will convene on TBC via Zoom to hear oral representations from the appellant.